title: Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.
abstract: To study the effects of adriamycin on the expression of BRCA1 and PARP-1 in BRCA1 wild-type MCF-7 cells. We used Western blotting to detect BRCA1 and PARP-1 levels in MCF-7 cells treated with adriamycin, and used flow cytometry to detect apoptotic MCF-7 cells. Results showed that adriamycin can increase PARP-1 activation in a dose- and time-dependent manner. BRCA1 levels were also increased upon treatment with a high dose of adriamycin, but gradually decreased over time. Treatment of MCF-7 cells with 3-ABA inhibited PARP-1 activity, but had no effect on BRCA1 levels. Compared to adriamycin and 3-ABA treatment alone, the co-treatment can increase the apoptosis of MCF-7 cells. Compared to BRCA1-defective HCC1937 cells, adriamycin combined with 3-ABA can further induce apoptosis of MCF-7 cells (P < 0.05). All of these suggested that adriamycin can affect the PARP-1 activation and the expression of BRCA1. Combined with 3-ABA has an additive effect on the rate of apoptosis observed.
authors.affiliation: Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.
authors.forename: Changqing
authors.initials: C
authors.lastname: Lu
authors.affiliation: Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Tan
authors.affiliation: Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Xie
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D019313:BRCA1 Protein / Q000235:genetics / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism*; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D000903:Antibiotics, Antineoplastic; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D001549:Benzamides; D004791:Enzyme Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D004317:Doxorubicin; C025160:3-aminobenzamide; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases
keywords: BRCA1; MCF-7; PARP-1; adriamycin